2005
DOI: 10.1124/mol.104.008615
|View full text |Cite|
|
Sign up to set email alerts
|

Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes

Abstract: Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT (a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of ␣CGRP, being a weak agonist at CT (a) , AMY 2(a) , and AMY… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

20
255
2

Year Published

2008
2008
2020
2020

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 191 publications
(284 citation statements)
references
References 34 publications
20
255
2
Order By: Relevance
“…However, due to the lack of selective pharmacological tools, significant complexity of this system and lack of specific RAMP antibodies, it has been difficult to confidently assign specific amylin functions to one of these receptor subtypes. Data from functional bioassays, including binding studies (16,29,30), demonstrate that AMY3, which is a heterodimeric complex of CTR and RAMP3, has a high affinity for amylin. Amylin receptor components (CTR and RAMPs) are reported to be distributed widely in the central nervous system with pronounced expression within spinal cord, brain stem, cortex, hypothalamus, and hippocampus (31,32).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, due to the lack of selective pharmacological tools, significant complexity of this system and lack of specific RAMP antibodies, it has been difficult to confidently assign specific amylin functions to one of these receptor subtypes. Data from functional bioassays, including binding studies (16,29,30), demonstrate that AMY3, which is a heterodimeric complex of CTR and RAMP3, has a high affinity for amylin. Amylin receptor components (CTR and RAMPs) are reported to be distributed widely in the central nervous system with pronounced expression within spinal cord, brain stem, cortex, hypothalamus, and hippocampus (31,32).…”
Section: Discussionmentioning
confidence: 99%
“…The CTR component of this receptor shares the same general GPCR architecture: seven membrane-spanning interconnected ␣-helices that transmit extracellular signals to the intracellular cytoplasmic signaling cascade. Activation of amylin receptors in mammalian cells has been shown previously to raise cAMP and presumed to involve G S protein (Gs ␣-guanine nucleotide-binding signal transduction protein) and stimulation of adenylate cyclase (16,17).…”
mentioning
confidence: 99%
“…The complex CTR/RAMP1 is classified as an amylin receptor, which explains the name AMY1, but has also a high affinity for CGRP and consequently is considered a dual CGRP/amylin receptor [68,69]. Both receptors, CGRP and AMY1, are strongly and equally represented in rat TG neurons since equipotent results are found when antagonizing each of them separately.…”
Section: The Receptormentioning
confidence: 99%
“…[52][53][54] Receptor binding and mapping studies have shown a wide distribution of the amylin receptor components throughout the central nervous system, and a high density of both the CTR and RAMPs is found in the AP. [55][56][57][58] Recent experiments in our laboratory have shown that single amylinactivated AP neurons contain all necessary components of the functional amylin receptor 1 or 3, that is, CTR plus RAMP1 or CTR plus RAMP3, respectively; in fact, AP neurons may often contain both types of RAMPs within single cells.…”
Section: Amylin and Glp-1 Receptor Functionmentioning
confidence: 99%